Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    TopAbstracts in Anxiety 10/28/2009 - (DGNews)
    TopAbstracts in Anxiety 10/14/2009 - (DGNews)
    TopAbstracts in Anxiety 09/30/2009 - (DGNews)
    Adjunctive Pregabalin Benefits Patients With Treatment-Resistant Generalised Anxiety Disorder: Presented at ECNP - (DGDispatch)
    Pregabalin Facilitates Successful Switch From Benzodiazepine Therapy in Patients With Generalised Anxiety Disorder: Presented at ECNP - (DGDispatch)

    News archive

     Recent webcasts/CME - Anxiety

    Webcasts/CME archive

     Recent cases - Anxiety
      Diagnosing and Managing Post-Traumatic Stress Disorder
      Chronic Dizziness Presenting in a Patient with Panic Disorder: Response to Imipramine
      Aripiprazole Augmentation in Poor Insight Obsessive-Compulsive Disorder: A Case Report
      Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report
      Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia Following Paroxetine Withdrawal: a Review of Rebound-Withdrawal Phenomena

      Cases archive
        




      my personal edition > anxiety > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Venlafaxine XR Demonstrates Efficacy in Panic Disorder: Presented at ADAA

      By Alison Palkhivala

      TORONTO, ON -- April 1, 2003 -- Venlafaxine extended release (XR) appears to be a safe and effective short-term treatment for panic disorder, according to an industry-sponsored study.

      Results were presented here in a poster on March 29th at the 23rd Annual Conference of the Anxiety Disorders Association of America.

      Timothy Whitaker, MD, Wyeth Research, Collegeville, Pennsylvania, led a multicenter trial in which 361 patients with panic disorder (with or without agoraphobia) were randomized to treatment with 75 to 225 mg/day of venlafaxine XR or placebo for up to 10 weeks. Wyeth is the manufacturer of venlafaxine XR.

      The researchers measured treatment efficacy using the Panic and Anticipatory Anxiety Scale (PAAS) and the Clinical Global Impression of Improvement (CGI-I) scale.

      After 10 weeks, 55% of patients receiving venlafaxine XR and 52.4% of patients receiving placebo were free from panic attacks, based on an intent-to-treat analysis. Overall, 68.1% of patients taking venlafaxine XR, compared with 55.4% of patients on placebo responded to therapy (P<0.05). Also, 35.6% of venlafaxine XR patients achieved remission, versus 24.4% of patients on placebo (P<0.05).

      Venlafaxine XR therapy was also better than placebo at reducing panic attack frequency. Patients on venlafaxine XR had a median change from baseline in panic attack frequency of -5, compared with -3.7 for those on placebo (P<0.05).

      Both the incidence and severity of adverse events that were associated with venlafaxine XR treatment for panic disorder in this study were comparable to those observed in patients with depression and generalized anxiety disorder treated with this agent. The most common adverse events included insomnia, dry mouth, sweating, sexual problems and constipation.


      [Study title: Treatment Of Panic Disorder With Venlafaxine XR. Abstract P89]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send